ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Illumina, Inc., a leader in DNA sequencing and array technologies, has launched a pilot proteomics program analyzing 50,000 UK Biobank samples. In collaboration with deCODE Genetics, GSK, Novartis, and others, the initiative utilizes Illumina’s next-gen proteomics assay, Protein Prep™, powered by SOMAmer® technology. This solution promises scalable access to proteomic insights, enabling advancements in drug discovery and disease research.
Proteomics, which examines protein functions and biomarkers, supports breakthroughs in cancer, cardiovascular disease, and other conditions. Illumina’s high-throughput Protein Prep technology enhances protein quantitative trait loci (pQTL) discovery, linking genetic variations to protein expression and disease phenotypes.
UK Biobank will contribute 50,000 samples, including 30,000 funded by Illumina, deCODE Genetics, and Standard BioTools. The samples will be processed using NovaSeq™ X Plus and the DRAGEN Protein Quantification pipeline. Data from these samples will be shared with researchers in 2025. For the remaining 20,000 samples, consortium members will receive exclusive access before release to the broader scientific community.
Illumina aims to deliver rich proteomics data to accelerate medical research. “This project will generate high-quality data, advancing biological insights for researchers and pharma partners,” said Steve Barnard, CTO of Illumina.
UK Biobank Principal Investigator Sir Rory Collins praised the program’s potential to enhance understanding of genetics, environment, and lifestyle in disease development. Standard BioTools CEO Michael Egholm highlighted the transformative potential of combining SOMAmer multiplexing with next-gen sequencing.
The Illumina Protein Prep assay detects 9,000 proteins using 11,000 SOMAmer reagents and supports multiomics studies on NovaSeq platforms. Full launch is expected in early 2025.
This pilot marks a milestone in proteomics, fostering collaboration between researchers and industry leaders to advance global healthcare.
